Follow Us

Faculty Of IDS 2022

Here are some of the International Speakers

Dr. Roy Taylor,UK

Dr. Roy Taylor qualified in medicine at the University of Edinburgh, and is Professor of Medicine and Metabolism at Newcastle University and Newcastle Hospitals NHS Trust. He has been conducting research on type 2 diabetes since 1978. Between 1985 and 2003 he developed the system now used throught the United Kingdom for screening for diabetic eye disease, with major reduction in blindness rates. He produced books for retinal screeners and co-founded the British Association of Retinal Screeners. He founded the Newcastle Magnetic Resonance Centre in 2006 to develop innovative techniques for all medical specialities but especially diabetes. In 2011 he showed that type 2 diabetes was a simple, reversible condition of excess fat within liver and pancreas and this led to a series of studies, including the Diabetes Remission Clinical Trial demonstrating that type 2 diabetes can be put into remission in routine Primary Care.


Share With:    Facebook WhatsApp Twitter

Dr. Annika Janson, Sweden

Dr. Annika Janson is the former Head of the Section for Diabetes, Endocrinology, Metabolic Disease and Obesity (DEMO) at the Karolinska University Hospital, the largest pediatrics endocrinology center among the Nordic countries. Her research focuses on clinical studies in ketoacidosis, insulin pumps therapy and bariatric surgery in adolescents.

Dr. Roger Mazze, USA

Dr. Roger Mazze received his PhD from the University of Illinois following a fellowship at Brandeis University's Lemberg Center. He joined the Albert Einstein College of Medicine faculty in 1974, and was promoted in 1987 to Professor. He was executive director of the Diabetes Research and Training Center and the first WHO Collaborating Center. In 1988 he became professor and senior vice president of the International Diabetes Center where he is credited with the development of the ambulatory glucose profile (AGP) as the first standardized report from SMBG and CGM. He also developed and directed the first WHO-recognized technology laboratory (under the auspices of the WHO Collaborating Center at the IDC and Mayo Clinic) Dr. Mazze was also a founder of the affiliated diabetes centre program at Nanjing Medical University where he is appointed visiting professor.

Dr. Suresh Chari, USA

Dr. Suresh Chari is a world-renowned expert in pancreatic diseases with over 250 publications to his name. He is currently Professor of Medicine at the Anderson Cancer Centre in Houston and is the President Elect of the International Association of Pancreatology. He is currently undertaking ground-breaking research into the onset of diabetes as an early marker of pancreatic cancer.

Dr. Prathibha Varkey, USA

Dr. Prathibha Varkey is the President of Mayo Clinic Health System and Professor of Medicine & of Preventive Medicine, at Mayo Clinic, College of Medicine and Science, USA. An internationally recognized expert in Quality Improvement, Dr. Varkey served as the President of the American College of Medical Quality. Dr. Varkey is the recipient of many awards including the American Medical Association Foundation Physician Leadership award, the American College of Medical Quality President's award, the Mayo Clinic individual excellence award and many more. She recently received the CT women of influence Corporate Leader Award. Dr. Varkey is internationally renowned for her leadership in health care.

Dr. Chirag Desai, USA

Chirag Desai, is the Director- Chronic Pancreatitis & Autologous-Islet Cell Transplant Program and Professor of Surgery at University of North Carolina at Chapel Hill, USA. Dr. Desai is one of a few surgical leaders in the U.S. who specializes in the field of chronic pancreatitis and autologous islet cell transplantation. He has published several manuscripts in the field, most notably a novel technique of surgery for total pancreatectomy for islet auto transplant.

Dr. Nils-Goran Larsson , Sweden

Dr. Nils-Goran Larsson is a professor in mitochondrial genetics at the Department of Laboratory Medicine at Karolinska Institute, Sweden. Dr. Larsson is also a senior consultant at the Center for Inherited Metabolic Diseases at the Karolinska university hospital. Dr. Larsson has reached international acclaim for his work, and has become one of the leading scientists within the field of mitochondrial genetics. Dr. Larsson is a member of the Nobel Assembly at the Karolinska Institute, and one of the current members of the Nobel Committee for Medicine or Physiology.

Dr. John Doupis, Greece

Dr. John Doupis, is director of the Diabetes Division of Iatriko Paleou Falirou Medical Center, Greece. His special areas of interest are type 1 and type 2 diabetes and its complications, including diabetic foot and obesity, as well as, glucose sensing technologies and insulin pumps.Dr. Doupis is a member of the Hellenic Diabetes Guidelines board and serves as an advisor of the national authority’s committee for insulin pumps and sensors. He is one of the foremost European experts in Diabetology

Dr. C.B Sanjeevi,Sweden

Dr. Carani B Sanjeevi MD, PhD is a Professor at the Karolinska Institute (KI) in the Department of Medicine. He heads a research group "Diabetes Immunology" at the Center for Molecular Medicine in Karolinska University Hospital, Solna campus in Stockholm. Dr. Sanjeevi is also Senior Advisor to the Innovation office of Karolinska Institute. He is considered to be a global authority in diabetes, particularly autoimmune diabetes.


Share With:    Facebook WhatsApp Twitter

Dr. Pankaj Shah, USA

Dr.Pankaj Shah is an Endocrinologist, at the Mayo Clinic, Rochester, MN, USA.Dr Shah trained and worked at the AIIMS, Delhi, prior to moving to Mayo Clinic, US in 1997. He has a rich international experience in endocrinology, having also worked at the Creighton University, MD Anderson Center and at University of Texas. Dr Shah is on the editorial board of Endocrine Practice. He is internationally renowned and has an interest in management of diabetes in patients with complex clinical conditions and also in hypoglycemia management.


Share With:    Facebook WhatsApp Twitter

Dr. Juliana Chan, Hong Kong

Prof. Juliana Chan is an internationally acclaimed clinician and researcher. She is the Founding Director of the Hon Kong Institute of Diabetes and Obesity, and is a professor at the Prince of Wales Hospital, Chinese University of Hong Kong. Dr. Chan's research has advanced our knowledge of epidemiology, genetics and clinical care in diabetes. Dr. Chan is a member of the steering committee for the prevention of non-communicable disease in Hong Kong . For her outstanding contribution, the ADA, conferred the HAROLD RIFKIN award on Dr Chan in 2019.


Share With:    Facebook WhatsApp Twitter

Dr. Ohad Cohen, Israel

Prof. Cohen is a Clinical Professor of Medicine at the Institute of Endocrinology, Chaim Sheba Medical Center, Tel - Aviv School of Medicine, and is also the Senior Medical Affairs Director for Global Medtronic Diabetes. He is active in development of the clinical pathway for the use of technology in the treatment of Diabetes, leading clinical trials as well as real world analysis of the use of technology in Diabetes. Prof. Cohen is also developing and running educational programs for Health care providers and people with Diabetes.

Dr. Michele Yeun, Hong Kong

Dr. Michele Yun is a well-known specialist in diabetes and obesity. Dr Michele practices in the city of Hong Kong. Dr. Michele is well-known for her interest in the care of people with obesity and type 2 diabetes. Dr. Michele is known to be an excellent academician and wonderful speaker. Dr Michele is renowned for her expertise in patient care.

Dr. Manjul Patwardhan, USA

Dr. Manjul Patwardhan practices in USA to provide total health care to patients with emphasis on patient education. Dr. Patwardhan specializes in Obesity Medicine with vision and focus to help improve Metabolic Syndrome, via lifestyle measures. Dr. Patwardhan has a special interest in treating obesity and type 2 diabetes in South Asian patients living in United States of America.

Dr. Vinaya Simha, USA

Dr. Vinaya Simha, MBBS, MD is a Consultant in the Division of Endocrinology, and Assistant Professor, Department of Internal Medicine at Mayo Clinic, Rochester, MN. He is board certified in Internal Medicine, Endocrinology and Clinical Lipidology. His research interests include lipodystrophy and the role of body fat distribution on glucose and lipid homeostasis, and has many publications in the field of lipodystrophy and leptin-replacement therapy. He has a keen interest in clinical lipidology and is an investigator in some of the early trials of PCSK9 inhibitors.

Dr. Ananda Basu, USA

Dr. Ananda Basu is the Harrison Professor in the Division of Endocrinology at the University of Virginia. He is the past Chair of the Hospital Diabetes Practice at Mayo Clinic. Dr. Basu is currently the Principal Investigator of two NIH funded projects- NIDDK-DP3-106785 that attempts to recreate a truly electronic beta cell by infusing insulin and amylin and NIDDK-R01-085516 that seeks to understand the altered physiology of the alpha cell in humans with and without type 1 diabetes. He is also a consultant in a project that seeks to introduce the first indigenous artificial pancreas for patients with type 1 diabetes. Dr. Basu is the author of almost 200 peer-reviewed publications in major journals including the New England Journal of Medicine, Journal of Clinical Investigation and Diabetes. He has been on the editorial board of Diabetes Care and currently is an Associate editor of the Diabetes Technology and Therapeutics journal.


Share With:    Facebook WhatsApp Twitter

Dr. Kamlesh Khunti,UK

Dr. Kamlesh Khunti is the professor of Primary Care Diabetes and Vascular Medicine, University of Leicester, UK. He is the Director of East Midlands CLAHRC and Co-director for the South East Midlands Diabetes Research Networks. He is currently an advisor to the Department of Health's National Screening Committee on Vascular Risk. He is also a senior advisor to the Department of Health to NICE, the South Asian Health Foundation and the European Society of Diabetes. He has over 692 publications in various major journals. His research into screening, risk assessment, obesity and vascular disease in diabetes, particularly in black and ethnic minority groups, has had numerous important impacts on clinical practice and policy.


Share With:    Facebook WhatsApp Twitter

Dr. Michael Chan,Hongkong

Dr. Michael Chan is a Faculty in Cardiology at the University of Hong Kong and he is also working in the Gleneagles Hong Kong Hospital. He is the fellow of the Hong Kong College of Cardiology, the Hong Kong College of Physicians, the Hong Kong Academy of Medicine, Royal College of Physicians of Edinburgh, Royal College of Physicians and Surgeons of Glasgow, and the American College of Cardiology. He obtained his doctoral degree in medicine with his thesis titled "Stroke Prevention in Atrial Fibrillation - From Atrial Fibrillation Screening to anticoagulation". His expertise includes percutaneous coronary intervention of complex coronary artery disease and minimally invasive trans-catheter valve therapies including trans-catheter aortic valve implantation and left atrial appendage occlusion. Dr. Chan has published over 60 peer-reviewed articles in major cardiology journals including JACC and Circulation.

Dr. Rita Basu, USA

Dr. Rita Basu is a Professor in the Division of Endocrinology at the University of Virginia. She is working on Translational Research for diabetes at UVA School of Medicine and Center for Diabetes Technology. She is currently the Principal Investigator on several NIH grants. She has had a long and productive career as an expert in the Ethics of Research and Human subject protection having served on the Institutional Review Board as the Associate Medical Director for 3 years and also a Chair of the IRB for over a decade at Mayo Clinic. She has authored more than 150 peer-review publications in diabetes. She has expertise in integrative physiology and translational research, ethical conduct of research, federal regulations guiding research and diabetes training and education.


Share With:    Facebook WhatsApp Twitter

Faculty Of IDS 2021

Here are some of the International Speakers

Dr. Melanie J. Davies, UK

Prof. Melanie J. Davies is and internationally acclaimed diabetes expert and the Professor of Diabetes Medicine at the University of Leicester, UK. She is a clinician with over 25 years experience working as a diabetologist and physician. She is an NIHR Senior Investigator, one of only a handful in diabetes in the UK. She was recently listed among the top ten global diabetes experts. She has also been the lead author for the ADA/EASD Diabetes Management Guidelines in 2018. She is the principal investigator on a number of large global studies in the field of diabetes, obesity and cardiovascular disease. In the last three years she has had more than 180 peer review publications.


Share With:    Facebook WhatsApp Twitter

Dr. Desmond Schatz, USA

Dr. Desmond Schatz is the former President of American Diabetes Association and professor in University of Florida. He is the professor and Associate Chairman of Pediatrics, Medical Director of the Diabetes Center and Associate Director of the GCRC at the University of Florida, Gainesville. He has been involved in Type 1 Diabetes research since the mid-80s and has published over 200 manuscripts, the majority related to the prediction, natural history, genetics, immunopathogenesis and prevention of the disease, as well as the management of children and adolescents with Type 1 Diabetes. He is the Principal Investigator (PI) on several JDRF and NIH awards. He serve as the president for the American Diabetes Association in 2016.

Dr. Juliana Chan, Hong Kong

Prof. Juliana Chan is an internationally acclaimed clinician and researcher. She is the Founding Director of the Hon Kong Institute of Diabetes and Obesity, and is a professor at the Prince of Wales Hospital, Chinese University of Hong Kong. Dr. Chan's research has advanced our knowledge of epidemiology, genetics and clinical care in diabetes. Dr. Chan is a member of the steering committee for the prevention of non-communicable disease in Hong Kong . For her outstanding contribution, the ADA, conferred the HAROLD RIFKIN award on Dr Chan in 2019.


Share With:    Facebook WhatsApp Twitter

Dr. Roy Taylor,UK

Dr. Roy Taylor qualified in medicine at the University of Edinburgh, and is Professor of Medicine and Metabolism at Newcastle University and Newcastle Hospitals NHS Trust. He has been conducting research on type 2 diabetes since 1978. Between 1985 and 2003 he developed the system now used throught the United Kingdom for screening for diabetic eye disease, with major reduction in blindness rates. He produced books for retinal screeners and co-founded the British Association of Retinal Screeners. He founded the Newcastle Magnetic Resonance Centre in 2006 to develop innovative techniques for all medical specialities but especially diabetes. In 2011 he showed that type 2 diabetes was a simple, reversible condition of excess fat within liver and pancreas and this led to a series of studies, including the Diabetes Remission Clinical Trial demonstrating that type 2 diabetes can be put into remission in routine Primary Care.


Share With:    Facebook WhatsApp Twitter

Dr. Amitha Domalpally, USA

Dr. Amitha Domalpally is Research Director at McPherson Eye Research Institute, University of Wisconsin, Madison, USA where the early and pioneering studies of diabetic retinopathy had been conducted. Dr. Domalpally is interested in ophthalmology imaging research and works to develop imaging outcomes for clinical trials, particularly in the field of diabetic retinopathy and macular degeneration. Dr. Domalpally also participates in National Eye Institute and National Institute of Health funded projects. Dr. Domalpally's research interest involves novel outcomes and new imaging techniques such as autofluorescence, spectral domain optical coherence tomography (OCT) layer segmentation and wide field photography and their validation for clinical trials. Dr. Domalpally has developed a grading methodology for evaluating peripheral retina. The method has been used in a large study involving over 1000 participants. Dr. Domalpally has a keen interest in research for the prevention and treatment of diabetic retinopathy.

Dr. Andrew JM Boulton, UK

Dr. Boulton is a Professor of Medicine at Manchester University. He has authored more than 500 peer-reviewed manuscripts and book chapters, mainly on diabetic lower limb and renal complications. Among his many awards, he has received the ADA's Roger Pecoraro Lectureship, the EASD Camillo Golgi prize and was the first recipient of the international award on diabetic foot research. He was the 2008 winner of the ADA's Harold Rifkin award for distinguished international service in diabetes. He is a previous editor of Diabetic Medicine and is currently an associate editor of Diabetes Care. He was the founding Chairman of the Diabetic Foot Study Group. He is current President of International Diabetes Federation.

Dr. Roger Mazze, USA

Dr. Roger Mazze received his PhD from the University of Illinois following a fellowship at Brandeis University's Lemberg Center. He joined the Albert Einstein College of Medicine faculty in 1974, and was promoted in 1987 to Professor. He was executive director of the Diabetes Research and Training Center and the first WHO Collaborating Center. In 1988 he became professor and senior vice president of the International Diabetes Center where he is credited with the development of the ambulatory glucose profile (AGP) as the first standardized report from SMBG and CGM. He also developed and directed the first WHO-recognized technology laboratory (under the auspices of the WHO Collaborating Center at the IDC and Mayo Clinic) Dr. Mazze was also a founder of the affiliated diabetes centre program at Nanjing Medical University where he is appointed visiting professor.

Dr. Michael Chan,Hongkong

Dr. Michael Chan is a Faculty in Cardiology at the University of Hong Kong and he is also working in the Gleneagles Hong Kong Hospital. He is the fellow of the Hong Kong College of Cardiology, the Hong Kong College of Physicians, the Hong Kong Academy of Medicine, Royal College of Physicians of Edinburgh, Royal College of Physicians and Surgeons of Glasgow, and the American College of Cardiology. He obtained his doctoral degree in medicine with his thesis titled "Stroke Prevention in Atrial Fibrillation - From Atrial Fibrillation Screening to anticoagulation". His expertise includes percutaneous coronary intervention of complex coronary artery disease and minimally invasive trans-catheter valve therapies including trans-catheter aortic valve implantation and left atrial appendage occlusion. Dr. Chan has published over 60 peer-reviewed articles in major cardiology journals including JACC and Circulation.

Dr.Michael S. Ip,USA

Dr.Michael S. Ip, MD, is Professor, Department of Ophthalmology at the University of California, Los Angeles, USA. He is a renowned ophthalmologist, with a special interest in the management of diabetic retinopathy. Dr. Ip's research focuses on the design and conduct of clinical trials investigating treatments for diabetic retinopathy, AMD, and retinal venous occlusive disease. He has assisted with the collection, analysis, and dissemination of important secondary outcomes in numerous NIH-funded ophthalmic clinical trials. Dr. Ip has been recognized with several honors, including the Senior Achievement Award and the Leadership Development Program Award, both from the American Academy of Ophthalmology.

Dr. Rita Basu, USA

Dr. Rita Basu is a Professor in the Division of Endocrinology at the University of Virginia. She is working on Translational Research for diabetes at UVA School of Medicine and Center for Diabetes Technology. She is currently the Principal Investigator on several NIH grants. She has had a long and productive career as an expert in the Ethics of Research and Human subject protection having served on the Institutional Review Board as the Associate Medical Director for 3 years and also a Chair of the IRB for over a decade at Mayo Clinic. She has authored more than 150 peer-review publications in diabetes. She has expertise in integrative physiology and translational research, ethical conduct of research, federal regulations guiding research and diabetes training and education.


Share With:    Facebook WhatsApp Twitter

Dr. Kaushik Ray,UK

Dr. Kaushik Ray is one of the most pre-eminent preventative cardiologists in the world, with over 40,000 citations and over 200 publications in top-quality peer-reviewed journals. He is the Professor of Public Health, Honorary Consultant Cardiologist, Head of Commercial Trials and Deputy Director of the Imperial Clinical Trials Unit at Imperial College London. He is the lead investigator for several major global medical trials of novel therapies for the prevention of cardiovascular disease. His research focuses on the prevention of coronary disease, in particular cholesterol, lipids, diabetes, biomarkers and risk prediction. Dr. Ray is one of the most pre-eminent preventative cardiologists in the world, with over 40,000 citations and over 200 publications in top-quality peer-reviewed journals. In addition to being a Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal Colleges of Physicians (London and Edinburgh, he is also a member of the British Cardiovascular Society and European Atherosclerosis Society (EAS).


Share With:    Facebook WhatsApp Twitter

Dr. Kamlesh Khunti,UK

Dr. Kamlesh Khunti is the professor of Primary Care Diabetes and Vascular Medicine, University of Leicester, UK. He is the Director of East Midlands CLAHRC and Co-director for the South East Midlands Diabetes Research Networks. He is currently an advisor to the Department of Health's National Screening Committee on Vascular Risk. He is also a senior advisor to the Department of Health to NICE, the South Asian Health Foundation and the European Society of Diabetes. He has over 692 publications in various major journals. His research into screening, risk assessment, obesity and vascular disease in diabetes, particularly in black and ethnic minority groups, has had numerous important impacts on clinical practice and policy.


Share With:    Facebook WhatsApp Twitter

Dr. Michael Roden,Germany

Professor Dr. Michael Roden is Chair of Endocrinology & Metabolic Diseases, Heinrich-Heine University, Director of the Division of Endocrinology & Diabetology, University Clinics Dusseldorf, and CEO of the German Diabetes Center. His translational studies address insulin resistance and energy metabolism using noninvasive technologies, and diabetes and its comorbidities, e.g. fatty liver disease. He has published 500+ peer-reviewed papers and received several international awards (e.g. Oskar-Minkowski Prize, Morgagni Gold Medal, Somogyi Award). He was President of the Central European and the Austrian Diabetes Associations and Congress President of the German Diabetes Association, is member of the German Council of Science & Humanities and elected EASD board member


Share With:    Facebook WhatsApp Twitter

Dr. C.B Sanjeevi,Sweden

Dr. Carani B Sanjeevi MD, PhD is a Professor at the Karolinska Institute (KI) in the Department of Medicine. He heads a research group "Diabetes Immunology" at the Center for Molecular Medicine in Karolinska University Hospital, Solna campus in Stockholm. Dr. Sanjeevi is also Senior Advisor to the Innovation office of Karolinska Institute. He is considered to be a global authority in diabetes, particularly autoimmune diabetes.


Share With:    Facebook WhatsApp Twitter

Dr. Pankaj Shah, USA

Dr.Pankaj Shah is an Endocrinologist, at the Mayo Clinic, Rochester, MN, USA.Dr Shah trained and worked at the AIIMS, Delhi, prior to moving to Mayo Clinic, US in 1997. He has a rich international experience in endocrinology, having also worked at the Creighton University, MD Anderson Center and at University of Texas. Dr Shah is on the editorial board of Endocrine Practice. He is internationally renowned and has an interest in management of diabetes in patients with complex clinical conditions and also in hypoglycemia management.


Share With:    Facebook WhatsApp Twitter

Dr. Vinaya Simha, USA

Dr. Vinaya Simha, MBBS, MD is a Consultant in the Division of Endocrinology, and Assistant Professor, Department of Internal Medicine at Mayo Clinic, Rochester, MN. He is board certified in Internal Medicine, Endocrinology and Clinical Lipidology. His research interests include lipodystrophy and the role of body fat distribution on glucose and lipid homeostasis, and has many publications in the field of lipodystrophy and leptin-replacement therapy. He has a keen interest in clinical lipidology and is an investigator in some of the early trials of PCSK9 inhibitors.

Dr. Ananda Basu, USA

Dr. Ananda Basu is the Harrison Professor in the Division of Endocrinology at the University of Virginia. He is the past Chair of the Hospital Diabetes Practice at Mayo Clinic. Dr. Basu is currently the Principal Investigator of two NIH funded projects- NIDDK-DP3-106785 that attempts to recreate a truly electronic beta cell by infusing insulin and amylin and NIDDK-R01-085516 that seeks to understand the altered physiology of the alpha cell in humans with and without type 1 diabetes. He is also a consultant in a project that seeks to introduce the first indigenous artificial pancreas for patients with type 1 diabetes. Dr. Basu is the author of almost 200 peer-reviewed publications in major journals including the New England Journal of Medicine, Journal of Clinical Investigation and Diabetes. He has been on the editorial board of Diabetes Care and currently is an Associate editor of the Diabetes Technology and Therapeutics journal.


Share With:    Facebook WhatsApp Twitter

Dr. William Rust, USA

Dr. William Rust is the Head, Seraxis, and former Director of Cell Biology at the American Type Culture Collection, USA. Dr. William Rust is among the eminent stem cell researchers in the world. Founder of Seraxis, his work has focused on clinical aspects of stem cell therapy in diabetes. He is a leader in embryonic stem cell therapeutics, and in induced pluripotent stem cell- based treatments. Dr Rust has worked in US and Singapore to develop cell therapies for diabetes and cardiovascular disease. He holds patents, has published in reputed journals, and has been awarded the President's Graduate Fellowship. He is currently working towards clinical studies on a practical cell-based therapy for insulin dependent diabetes.

Dr. Paul Zimmet, Australia

Dr. Paul Zimmet is Professor of Diabetes at Monash University and formerly Director Emeritus, Baker Heart and Diabetes Institute, Australia. He is Honorary President of the International Diabetes Federation and has an extensive international record in diabetes and obesity research. His research predicted and has charted the evolving global type 2 diabetes epidemic. Dr. Zimmet is renowned for his contribution to understanding gestational diabetes and in the field of Circadian Rhythm and Diabetes.

Dr. Peter Lin, Canada

Dr. Peter Lin began his studies in the Faculty of Science and Engineering at the University of Toronto in Toronto, Canada. He served as the medical director at the Health & Wellness Centre, University of Toronto Scarborough, for 7 years. Currently, he is the Director of Primary Care Initiatives at the Canadian Heart Research Centre. Dr. Lin was a consultant for Perspectives in Cardiology, and was on the editorial board of The Canadian Review of Alzheimer's Disease and Other Dementias. He had been the chairman of the Dementia Congress in the US for 4 years. He has also served on the editorial board of Pri-Med. Dr. Lin received a teaching award from the College of Family Physicians in 2011.

Dr. Ele Ferrannini, Italy

Dr. Ele Ferrannini is the recipient of the 2020 Banting Medal of the American Diabetes Association for Scientific Achievement. This award recognizes significant, long-term contributions to the understanding, treatment or prevention of diabetes. Currently he is a senior research associate at the National Research Council (CNR) Institute of Clinical Physiology and professor of medicine at the University of Pisa,Italy. Dr. Ferrannini is renowned for his contributions to the fields of insulin resistance and associated disorders (hypertension, dyslipidemia), B-cell function and dysfunction in vivo, the incretin effect, and the cardiovascular complications of diabetes. Dr. Ferrannini has also done pioneering work in therapeutics, including DPP-4 and SGLT2 inhibition and bariatric surgery. His ultimate vision is to explain diabetes as the result of integrated multiorgan responses that confer to the hyperglycemia the risk of both macro- and microvascular complications. Dr. Ferrannini's illustrious contributions have been recognized by prestigious honors including the Claude Bernard Award of the European Association for the Study of Diabetes, and honorary doctorates from the Universities of Turku (Finland) and the University of Patras (Greece).

Dr. Lars Ryden, Sweden

Dr. Lars Ryden is Senior Professor of Cardiology at the Karolinska Institute, Stockholm, Sweden. He specializes in internal medicine and cardiology, with a focus on heart failure and cardiovascular disease related to diabetes. Professor Ryden has published more than 700 scientific papers. He is an honorary member of the Royal College of Physicians, London, UK, and several national cardiac societies. Prof Ryden chaired the Task Forces that prepared the 2007 and 2013 ESC/EASD Guidelines for Diabetes, Prediabetes and Cardiovascular Disease.

Dr. Mikael Ryden, Sweden

Mikael Ryden is professor in clinical and experimental adipose tissue research and heads the Center for Clinical Metabolic Research in Diabetes at Karolinska Institutet. He is also senior consultant at the Endocrinology Unit Karolinska University Hospital, Stockholm, Sweden. His research focuses on the role of human adipose tissue in several different conditions and spans from advanced cell- and molecular biology techniques in different cell culture models to clinical studies in man.

Faculty Of IDS 2020

Here are some of the International Speakers

Dr. Michael Roden,Germany

Professor Dr. Michael Roden is Chair of Endocrinology & Metabolic Diseases, Heinrich-Heine University, Director of the Division of Endocrinology & Diabetology, University Clinics Dusseldorf, and CEO of the German Diabetes Center. His translational studies address insulin resistance and energy metabolism using noninvasive technologies, and diabetes and its comorbidities, e.g. fatty liver disease. He has published 500+ peer-reviewed papers and received several international awards (e.g. Oskar-Minkowski Prize, Morgagni Gold Medal, Somogyi Award). He was President of the Central European and the Austrian Diabetes Associations and Congress President of the German Diabetes Association, is member of the German Council of Science & Humanities and elected EASD board member


Share With:    Facebook WhatsApp Twitter

Dr. Roy Taylor,UK

Dr. Roy Taylor qualified in medicine at the University of Edinburgh, and is Professor of Medicine and Metabolism at Newcastle University and Newcastle Hospitals NHS Trust. He has been conducting research on type 2 diabetes since 1978. Between 1985 and 2003 he developed the system now used throught the United Kingdom for screening for diabetic eye disease, with major reduction in blindness rates. He produced books for retinal screeners and co-founded the British Association of Retinal Screeners. He founded the Newcastle Magnetic Resonance Centre in 2006 to develop innovative techniques for all medical specialities but especially diabetes. In 2011 he showed that type 2 diabetes was a simple, reversible condition of excess fat within liver and pancreas and this led to a series of studies, including the Diabetes Remission Clinical Trial demonstrating that type 2 diabetes can be put into remission in routine Primary Care.


Share With:    Facebook WhatsApp Twitter

Dr. Rita Basu, USA

Dr. Rita Basu is a Professor in the Division of Endocrinology at the University of Virginia. She is working on Translational Research for diabetes at UVA School of Medicine and Center for Diabetes Technology. She is currently the Principal Investigator on several NIH grants. She has had a long and productive career as an expert in the Ethics of Research and Human subject protection having served on the Institutional Review Board as the Associate Medical Director for 3 years and also a Chair of the IRB for over a decade at Mayo Clinic. She has authored more than 150 peer-review publications in diabetes. She has expertise in integrative physiology and translational research, ethical conduct of research, federal regulations guiding research and diabetes training and education.


Share With:    Facebook WhatsApp Twitter
.

Dr. Juliana Chan, Hong Kong

Prof. Juliana Chan is an internationally acclaimed clinician and researcher. She is the Founding Director of the Hon Kong Institute of Diabetes and Obesity, and is a professor at the Prince of Wales Hospital, Chinese University of Hong Kong. Dr. Chan's research has advanced our knowledge of epidemiology, genetics and clinical care in diabetes. Dr. Chan is a member of the steering committee for the prevention of non-communicable disease in Hong Kong . For her outstanding contribution, the ADA, conferred the HAROLD RIFKIN award on Dr Chan in 2019.


Share With:    Facebook WhatsApp Twitter

Dr. Kaushik Ray,UK

Dr. Kaushik Ray is one of the most pre-eminent preventative cardiologists in the world, with over 40,000 citations and over 200 publications in top-quality peer-reviewed journals. He is the Professor of Public Health, Honorary Consultant Cardiologist, Head of Commercial Trials and Deputy Director of the Imperial Clinical Trials Unit at Imperial College London. He is the lead investigator for several major global medical trials of novel therapies for the prevention of cardiovascular disease. His research focuses on the prevention of coronary disease, in particular cholesterol, lipids, diabetes, biomarkers and risk prediction. Dr. Ray is one of the most pre-eminent preventative cardiologists in the world, with over 40,000 citations and over 200 publications in top-quality peer-reviewed journals. In addition to being a Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal Colleges of Physicians (London and Edinburgh, he is also a member of the British Cardiovascular Society and European Atherosclerosis Society (EAS).


Share With:    Facebook WhatsApp Twitter

Dr. Melanie J. Davies, UK

Prof. Melanie J. Davies is and internationally acclaimed diabetes expert and the Professor of Diabetes Medicine at the University of Leicester, UK. She is a clinician with over 25 years experience working as a diabetologist and physician. She is an NIHR Senior Investigator, one of only a handful in diabetes in the UK. She was recently listed among the top ten global diabetes experts. She has also been the lead author for the ADA/EASD Diabetes Management Guidelines in 2018. She is the principal investigator on a number of large global studies in the field of diabetes, obesity and cardiovascular disease. In the last three years she has had more than 180 peer review publications.


Share With:    Facebook WhatsApp Twitter

Dr. Ananda Basu, USA

Dr. Ananda Basu is the Harrison Professor in the Division of Endocrinology at the University of Virginia. He is the past Chair of the Hospital Diabetes Practice at Mayo Clinic. Dr. Basu is currently the Principal Investigator of two NIH funded projects- NIDDK-DP3-106785 that attempts to recreate a truly electronic beta cell by infusing insulin and amylin and NIDDK-R01-085516 that seeks to understand the altered physiology of the alpha cell in humans with and without type 1 diabetes. He is also a consultant in a project that seeks to introduce the first indigenous artificial pancreas for patients with type 1 diabetes. Dr. Basu is the author of almost 200 peer-reviewed publications in major journals including the New England Journal of Medicine, Journal of Clinical Investigation and Diabetes. He has been on the editorial board of Diabetes Care and currently is an Associate editor of the Diabetes Technology and Therapeutics journal.


Share With:    Facebook WhatsApp Twitter

Dr. Kamlesh Khunti,UK

Dr. Kamlesh Khunti is the professor of Primary Care Diabetes and Vascular Medicine, University of Leicester, UK. He is the Director of East Midlands CLAHRC and Co-director for the South East Midlands Diabetes Research Networks. He is currently an advisor to the Department of Health's National Screening Committee on Vascular Risk. He is also a senior advisor to the Department of Health to NICE, the South Asian Health Foundation and the European Society of Diabetes. He has over 692 publications in various major journals. His research into screening, risk assessment, obesity and vascular disease in diabetes, particularly in black and ethnic minority groups, has had numerous important impacts on clinical practice and policy.


Share With:    Facebook WhatsApp Twitter

Dr. C.B Sanjeevi,Sweden

Dr. Carani B Sanjeevi MD, PhD is a Professor at the Karolinska Institute (KI) in the Department of Medicine. He heads a research group "Diabetes Immunology" at the Center for Molecular Medicine in Karolinska University Hospital, Solna campus in Stockholm. Dr. Sanjeevi is also Senior Advisor to the Innovation office of Karolinska Institute. He is considered to be a global authority in diabetes, particularly autoimmune diabetes.


Share With:    Facebook WhatsApp Twitter

Dr. Pankaj Shah, USA

Dr.Pankaj Shah is an Endocrinologist, at the Mayo Clinic, Rochester, MN, USA.Dr Shah trained and worked at the AIIMS, Delhi, prior to moving to Mayo Clinic, US in 1997. He has a rich international experience in endocrinology, having also worked at the Creighton University, MD Anderson Center and at University of Texas. Dr Shah is on the editorial board of Endocrine Practice. He is internationally renowned and has an interest in management of diabetes in patients with complex clinical conditions and also in hypoglycemia management.


Share With:    Facebook WhatsApp Twitter

Faculty Of IDS 2019

Dr. Ananda Basu, USA

Dr. Ananda Basu is the Harrison Professor in the Division of Endocrinology at the University of Virginia. He is the past Chair of the Hospital Diabetes Practice at Mayo Clinic. Dr. Basu is currently the Principal Investigator of two NIH funded projects- NIDDK-DP3-106785 that attempts to recreate a truly electronic beta cell by infusing insulin and amylin and NIDDK-R01-085516 that seeks to understand the altered physiology of the alpha cell in humans with and without type 1 diabetes. He is also a consultant in a project that seeks to introduce the first indigenous artificial pancreas for patients with type 1 diabetes. Dr. Basu is the author of almost 200 peer-reviewed publications in major journals including the New England Journal of Medicine, Journal of Clinical Investigation and Diabetes. He has been on the editorial board of Diabetes Care and currently is an Associate editor of the Diabetes Technology and Therapeutics journal.

Dr. Andrew JM Boulton, UK

Dr. Boulton is a Professor of Medicine at Manchester University. He has authored more than 500 peer-reviewed manuscripts and book chapters, mainly on diabetic lower limb and renal complications. Among his many awards, he has received the ADA's Roger Pecoraro Lectureship, the EASD Camillo Golgi prize and was the first recipient of the international award on diabetic foot research. He was the 2008 winner of the ADA's Harold Rifkin award for distinguished international service in diabetes. He is a previous editor of Diabetic Medicine and is currently an associate editor of Diabetes Care. He was the founding Chairman of the Diabetic Foot Study Group. Until recently he was President of the EASD.

Dr. C.B Sanjeevi, Sweden

Dr. Carani B Sanjeevi MD, PhD is a Professor at the Karolinska Institute (KI) in the Department of Medicine. He heads a research group "Diabetes Immunology" at the Center for Molecular Medicine in Karolinska University Hospital, Solna campus in Stockholm. Dr. Sanjeevi is also Senior Advisor to the Innovation office of Karolinska Institute. He is considered to be a global authority in diabetes, particularly autoimmune diabetes.

Prof. Leif Groop, Sweden

Prof. Leif Groop is a Professor in Endocrinology at Lund University and Director of Lund University Diabetes Centre. He is also Academy of Finland Finnish Distinguished Professor (FiDiPro) at the Institute for Molecular Medicine Finland (FIMM). After a PostDoc period at Yale University he devoted his research to dissection of the heterogeneity of diabetes and to explore the pathogenic events leading to type 2 diabetes. He initiated the Botnia Study in Finland, one of the world's largest family studies on type 2 diabetes. The research group has been involved in many of the genetic discoveries on type 2 diabetes during the past 15 years, including one of the first whole genome association studies for type 2 diabetes. His ground breaking paper on the different subtypes of diabetes this year has been making wave worldwide.

Dr. Loretta Vileikyte,UK

Dr. Vileikyte is a senior Lecturer in Medicine at the University of Manchester, UK. She has been active in clinical research of diabetic foot complication for over 25 years. Dr. Vileikyte has a special interest in diabetic neuropathy, and she has conducted several multicenter/ multidisciplinary transatlantic research projects. She has been working on cognitive-emotional representation of neuropathy and their role in foot self-care. An NIH project led by Dr. Vileikyte has generated one of the largest foot ulcer tissue databases, and she has been committed to the study of biological and behavioural visit factors for neuropathy and foot ulcer tissue.

Dr. Olle Ljungqvist,Sweden

Dr. Olle Ljungqvist is a Professor at Orebro University, Sweden. He has received his medical degree and obtained his PhD on Glucose Metabolism at the Karolinska Institute in Sweden. He has served as Chair of the European Society for Clinical Nutrition (ESPEN), the International Association for Surgical Metabolism and Nutrition (IASMEN) as part of the International Surgical Society. He co-founded the Enhanced Recovery After Surgery (ERAS) Society 2010 and serves as the Executive Chairman. He first proposed the use of preoperative carbohydrates instead of overnight fasting for elective surgery, a guideline that is recommended world-wide. His research interests are surgical stress, metabolism and nutrition and outcomes, publishing more than 200 original contributions, international guidelines, book chapters and reviews.He has co-edited several international textbooks on Clinical Nutrition and on ERAS. He has special interest and experience in how glucose metabolism and insulin resistance both influence perioperative medical care.

Dr. Pankaj Shah, USA

Dr.Pankaj Shah is an Endocrinologist, at the Mayo Clinic, Rochester, MN, USA.Dr Shah trained and worked at the AIIMS, Delhi, prior to moving to Mayo Clinic, US in 1997. He has a rich international experience in endocrinology, having also worked at the Creighton University, MD Anderson Center and at University of Texas. Dr Shah is on the editorial board of Endocrine Practice. He is internationally renowned and has an interest in management of diabetes in patients with complex clinical conditions and also in hypoglycemia management.

Dr. Rita Basu, USA

Dr. Rita Basu is a Professor in the Division of Endocrinology at the University of Virginia. She is working on Translational Research for diabetes at UVA School of Medicine and Center for Diabetes Technology. She is currently the Principal Investigator on several NIH grants. She has had a long and productive career as an expert in the Ethics of Research and Human subject protection having served on the Institutional Review Board as the Associate Medical Director for 3 years and also a Chair of the IRB for over a decade at Mayo Clinic. She has authored more than 150 peer-review publications in diabetes. She has expertise in integrative physiology and translational research, ethical conduct of research, federal regulations guiding research and diabetes training and education.

Dr. Suresh Chari, USA

Dr. Suresh Chari is currently Professor of Medicine at Mayo College of Medicine, Rochester, M.N. He has been the Director of Pancreas Clinic at Mayo Clinic, Rochester and past President of the American Pancreatic Association. He has been a Councellor of the International Association of Pancreatology(IAP) and is the President Elect of the IAP. He has over 250 (277) publications in the field of pancreatology. His research spans the breadth of pancreatic diseases including tropical chronic pancreatitis and pancreatic cancer. He has had NIH funding since 2003 for study of new- onset Diabetes as an early marker of pancreatic cancer. His current project, "Pancreatic Cancer-induced Diabetes: A Clue to its Early Diagnosis" has the long-term programmatic goals to facilitate early detection of pancreatic cancer. He is also interested in the effects of type 1 and type 2 Diabetes on the exocrine pancreas, a condition that he has termed " Diabetic exocrine pancreatopathy".

Professor Susan Wong, UK

Prof. Susan Wong is a Professor of Diabetes and Metabolism, at Cardiff University, UK. She has many years of research experience in working on the aetiology and pathogenesis of type 1 diabetes. Prof. Wong has also included the role of the gut microbiome. As a member of the Type 1 Diabetes Consortium, she has also been involved in translational work in developing immunotherapy for type 1 diabetes and in early phase 1a clinical trials.

Dr. Vinaya Simha, USA

Dr. Vinaya Simha, MBBS, MD is a Consultant in the Division of Endocrinology, and Assistant Professor, Department of Internal Medicine at Mayo Clinic, Rochester, MN. He is board certified in Internal Medicine, Endocrinology and Clinical Lipidology. His research interests include lipodystrophy and the role of body fat distribution on glucose and lipid homeostasis, and has many publications in the field of lipodystrophy and leptin-replacement therapy. He has a keen interest in clinical lipidology and is an investigator in some of the early trials of PCSK9 inhibitors.

Faculty Of IDS 2018

Dr. Ananda Basu, USA

Dr. Ananda Basu is a Professor of Medicine in the Division of Endocrinology, Mayo Clinic Rochester, USA. He is the past Chair of the Hospital Diabetes Practice at Mayo Clinic. His clinical accomplishments include standardizing and protocolizing care of all inpatients at Mayo Clinic Hospitals. His research work relates to the development of individualized, physiology-informed artificial pancreas closed loop systems for management of Type 1 diabetes and in integrated physiology of carbohydrate metabolism in humans. He has authored more than 175 original articles, book chapters and reviews on pathophysiology of diabetes. Dr. Basu is a principal investigator on several NIH grants. He is a "Clinician-Investigator" at Mayo Clinic and appointed as one of the 50 best doctors ever employed at the Mayo Clinic.

Dr. Andrew JM Boulton, UK

Dr. Boulton is a Professor of Medicine at Manchester University. He has authored more than 500 peer-reviewed manuscripts and book chapters, mainly on diabetic lower limb and renal complications. Among his many awards, he has received the ADA's Roger Pecoraro Lectureship, the EASD Camillo Golgi prize and was the first recipient of the international award on diabetic foot research. He was the 2008 winner of the ADA's Harold Rifkin award for distinguished international service in diabetes. He is a previous editor of Diabetic Medicine and is currently an associate editor of Diabetes Care. He was the founding Chairman of the Diabetic Foot Study Group. Until recently he was President of the EASD.

Dr. C.B Sanjeevi, Sweden

Dr. Carani B Sanjeevi MD, PhD is a Professor at the Karolinska Institute (KI) in the Department of Medicine. He heads a research group "Diabetes Immunology" at the Center for Molecular Medicine in Karolinska University Hospital, Solna campus in Stockholm. Dr. Sanjeevi is also Senior Advisor to the Innovation office of Karolinska Institute. Dr. Sanjeevi serves in the Board of Cadila Pharma Sweden AB, Oncology Ventures, Denmark and serves as member of the Scientific Advisory Board of Seraxis, USA and Diamyd Medical AB, Sweden. He is advisor to HBM Bioventures, Switzerland and TATA Capital Healthcare Private Equity Fund, Mumbai.

Dr. David Leslie, UK

Dr. David Leslie is Professor of Diabetes and Autoimmunity at St Bartholomew's Hospital and University of London. He was recently elected President of The Association of Physicians of Great Britian and Ireland. He has an interest in the cause of autoimmune diabetes through the study of twins and disease syndromes. David Leslie is the Reviews Editor of Diabetic Medicine and was on the Editorial Board of several major Journals. He is Director of the European Consortium Action LADA, Director of the British Diabetic Twin Trust, a member of the NIH Advisory Board on the Prevention of Diabetes, and is a Trustee of the British Twin Trust and the Muirhead Trust. He is an internationally renowned authority in the field of diabetes and autoimmunity.

Dr. Desmond Schatz, USA

President of ADA and professor in University of Florida, Dr Schatz is Professor and Associate Chairman of Pediatrics, Medical Director of the Diabetes Center and Associate Director of the GCRC at the University of Florida, Gainesville. He has been involved in Type 1 Diabetes research since the mid-80s and has published over 200 manuscripts, the majority related to the prediction, natural history, genetics, immunopathogenesis and prevention of the disease, as well as the management of children and adolescents with Type 1 Diabetes. He is the Principal Investigator (PI) on several JDRF and NIH awards. He serve as the president for the American Diabetes Association in 2016.

Dr Eva Ortqvist, Sweden

Dr Eva Ortqvist is an internationally renowned Paediatric Endocrinologist, who is a consultant at the Karolinska institute in Stockholm. She has extensive experience and publication in the field of childhood and adolescent diabetes. She is recognised as an international expert in the use of insulin pump therapy and in the autoimmune markers of Type 1 diabetes as well as autoimmune thyroid disease.

Dr. Massimo Porta, Italy

Massimo Porta a Professor at The Turin University was granted his PhD at the Royal Postgraduate Medical School, London University, UK in 1983, where he worked on diabetic eye disease. Currently, he is Head of the Unit of Internal Medicine and of the Diabetic Retinopathy Centre. Professor Porta is Past-President of the Study Group on Eye Complications of Diabetes of the European Association for the Study of Diabetes (EASDec), and Convenor of the Working Group of the Saint-Vincent Declaration for the prevention of Diabetes-Related Blindness in Europe, supported by the World Health Organization and the International Diabetes Federation (1985-95) and Honorary Secretary of the European Association for the Study of Diabetes (EASD) in 1999-2001. Professor Porta's research interests include the pathogenesis of diabetic retinopathy, prevention of diabetes-related blindness and Group Care, a new model to manage chronic diseases. Professor Porta has authored 168 papers in indexed journals, 101 other articles, 44 chapters, and edited or co-edited 13 books/monographs. He is Editor-in-Chief of Acta Diabetologica (IF 2015 3.079

Dr Michael Alvarsson , Sweden

Dr Michael Alvarsson is a professor at Karolinska University, working at the Clinic of Endocrinology, Metabolism and Diabetes. He also conducts clinical diabetes research at the Department of Molecular medicine and Surgery (MMK) at Karolinska Institute. He is widely known for his clinical studies on B-cell rest and the hypothalamo-pituitary- adrenal axis on metabolic control in diabetics and clinical studies on the effects of training on patients with type 2-diabetes. Some of his recent publications include- effect of high dose of Vitamin D on beta cell function (an RCT), gender differences in type 2 diabetes course/ outcomes, and ACTH sensitivity in diabetes.

Dr. Peter Adolfsson, Sweden

Dr. Peter Adolfsson, an internationally well known expert on advances in diabetes therapy, is a Faculty at the Institution for Clinical Sciences, Sahlgrenska Academy, at University of Gothenburg, Sweden. His research has centered around the use of technology in type 1 diabetes, and he is renowned for his work on the same. He has co-authored the exercise guideline-related consensus statement of the International Society of Pediatric and Adolescent Diabetes. An expert on insulin pumps and continuous glucose monitoring, the he is also working on projects that attempt to solve the special needs of chidren with type 1 diabetes. His work has been well cited, and has been published in journals such as Pediatric Diabetes, Diabetes Technology and Therapuetics and Diabetes Medicine.

Dr. Rita Basu, USA

Dr. Rita Basu is a Professor of Medicine in the Division of Endocrinology, Mayo Clinic Rochester, USA. She is Chair of the Institutional Review Board for the Mayo Clinic. She is Co-Director of international educational programs set up under WHO. Her research spans two decades and focuses on clinical and translational medicine related to Diabetes. Her current work relates to overnight glucose control in type 2 diabetes, clinical trials in NAFLD/NASH, novel glucose sensing and the development of an artificial pancreas. Dr. Basu is principal investigator on multiple NIH, Foundation and Industry grants. She has authored more than 120 original articles, books, and chapters on diabetes.

Dr. Vinaya Simha, USA

Dr. Vinaya Simha, MBBS, MD is a Consultant in the Division of Endocrinology, and Assistant Professor, Department of Internal Medicine at Mayo Clinic, Rochester, MN. He is board certified in Internal Medicine, Endocrinology and Clinical Lipidology. His research interests include lipodystrophy and the role of body fat distribution on glucose and lipid homeostasis, and has many publications in the field of lipodystrophy and leptin-replacement therapy. He has a keen interest in clinical lipidology and is an investigator in some of the early trials of PCSK9 inhibitors.

Dr. Ake Ortqvist, Sweden

Dr Ake Ortqvist is a faculty at Karolinska Institute. He is the former Head of Department of Infectious Disease at Karolinska University Hospital. He also headed the Department of Communicable Disease Control in Stockholm County, Sweden. He is an authority in influenza and pneumococcal vaccinations. Dr Ake has special expertise on vaccination strategies in high risk subjects such as people with diabetes. He will be talking on prevention of influenza in people with diabetes and the clinical strategies for vaccination in diabetes.




International Speakers of IDS 2017

Dr. Ananda Basu, USA

Dr. Ananda Basu is a Professor of Medicine in the Division of Endocrinology, Mayo Clinic Rochester, USA. He is the past Chair of the Hospital Diabetes Practice at Mayo Clinic. His clinical accomplishments include standardizing and protocolizing care of all inpatients at Mayo Clinic Hospitals. His research work relates to the development of individualized, physiology-informed artificial pancreas closed loop systems for management of Type 1 diabetes and in integrated physiology of carbohydrate metabolism in humans. He has authored more than 175 original articles, book chapters and reviews on pathophysiology of diabetes. Dr. Basu is a principal investigator on several NIH grants. He is a "Clinician-Investigator" at Mayo Clinic and appointed as one of the 50 best doctors ever employed at the Mayo Clinic.

Dr. Annika Janson, Sweden

Dr. Annika Janson is the former Head of the Section for Diabetes, Endocrinology, Metabolic Disease and Obesity (DEMO) at the Karolinska University Hospital, the largest pediatrics endocrinology center among the Nordic countries. Her research focuses on clinical studies in ketoacidosis, insulin pumps therapy and bariatric surgery in adolescents.

Dr. C.B Sanjeevi, Sweden

Dr. Carani B Sanjeevi MD, PhD is a Professor at the Karolinska Institute (KI) in the Department of Medicine. He heads a research group "Diabetes Immunology" at the Center for Molecular Medicine in Karolinska University Hospital, Solna campus in Stockholm. Dr. Sanjeevi is also Senior Advisor to the Innovation office of Karolinska Institute. Dr. Sanjeevi serves in the Board of Cadila Pharma Sweden AB, Oncology Ventures, Denmark and serves as member of the Scientific Advisory Board of Seraxis, USA and Diamyd Medical AB, Sweden. He is advisor to HBM Bioventures, Switzerland and TATA Capital Healthcare Private Equity Fund, Mumbai.

Dr. Lars Ryden, Sweden

Dr. Lars Ryden is Senior Professor of Cardiology at the Karolinska Institute, Stockholm, Sweden. He specializes in internal medicine and cardiology, with a focus on heart failure and cardiovascular disease related to diabetes. Professor Ryden has published more than 700 scientific papers. He is an honorary member of the Royal College of Physicians, London, UK, and several national cardiac societies. Prof Ryden chaired the Task Forces that prepared the 2007 and 2013 ESC/EASD Guidelines for Diabetes, Prediabetes and Cardiovascular Disease.

Dr. Linda Mellbin, Sweden

Dr. Linda Mellbin from the Karolinska University, Dr Mellbin currently works as senior cardiologist at the Coronary Care Unit since 2009. She obtained her PhD in 2010 with her studies on glucose-controls a research group "Diabetes Immunology" at the Center for Molecular Medicine in Karolinska University Hospital, Solna campus in Stockholm. Dr. Sanjeevi is also Senior Advisor to the Innovation office of Karolinska Institute. Dr. Sanjeevi serves in the Board of Cadila Pharma Sweden AB, Oncology Ventures, Denmark and serves as member of the Scientific Advisory Board of Seraxis, USA and Diamyd Medical AB, Sweden. He is advisor to HBM Bioventures, Switzerland and TATA Capital Healthcare Private Equity Fund, Mumbai.

Dr. Lars Ryden, Sweden

Dr. Lars Ryden is Senior Professor of Cardiology at the Karolinska Institute, Stockholm, Sweden. He specializes in internal medicine and cardiology, with a focus on heart failure and cardiovascular disease related to diabetes. Professor Ryden has published more than 700 scientific papers. He is an honorary member of the Royal College of Physicians, London, UK, and several national cardiac societies. Prof Ryden chaired the Task Forces that prepared the 2007 and 2013 ESC/EASD Guidelines for Diabetes, Prediabetes and Cardiovascular Disease.

Dr. Linda Mellbin, Sweden

Dr. Linda Mellbin from the Karolinska University, Dr Mellbin currently works as senior cardiologist at the Coronary Care Unit since 2009. She obtained her PhD in 2010 with her studies on glucose-control therapies and biomarkers in myocardial infarction and Diabetes. Dr. Mellbin has continued her research in the field of biomarkers, in particular related to hormonal systems. She participates in several clinical trials on Diabetes and cardiovascular disease.

Dr. Peter Adolfsson, Sweden

Dr. Peter Adolfsson, an internationally well known expert on advances in diabetes therapy, is a Faculty at the Institution for Clinical Sciences, Sahlgrenska Academy, at University of Gothenburg, Sweden. His research has centered around the use of technology in type 1 diabetes, and he is renowned for his work on the same. He has co-authored the exercise guideline-related consensus statement of the International Society of Pediatric and Adolescent Diabetes. An expert on insulin pumps and continuous glucose monitoring, the he is also working on projects that attempt to solve the special needs of chidren with type 1 diabetes. His work has been well cited, and has been published in journals such as Pediatric Diabetes, Diabetes Technology and Therapuetics and Diabetes Medicine.

Dr. Rita Basu, USA

Dr. Rita Basu is a Professor of Medicine in the Division of Endocrinology, Mayo Clinic Rochester, USA. She is Chair of the Institutional Review Board for the Mayo Clinic. She is Co-Director of international educational programs set up under WHO. Her research spans two decades and focuses on clinical and translational medicine related to Diabetes. Her current work relates to overnight glucose control in type 2 diabetes, clinical trials in NAFLD/NASH, novel glucose sensing and the development of an artificial pancreas. Dr. Basu is principal investigator on multiple NIH, Foundation and Industry grants. She has authored more than 120 original articles, books, and chapters on diabetes.

Dr. Roger Mazze, USA

Dr. Roger Mazze received his PhD from the University of Illinois following a fellowship at Brandeis University's Lemberg Center. He joined the Albert Einstein College of Medicine faculty in 1974, and was promoted in 1987 to Professor. He was executive director of the Diabetes Research and Training Center and the first WHO Collaborating Center. In 1988 he became professor and senior vice president of the International Diabetes Center where he is credited with the development of the ambulatory glucose profile (AGP) as the first standardized report from SMBG and CGM. He also developed and directed the first WHO-recognized technology laboratory (under the auspices of the WHO Collaborating Center at the IDC and Mayo Clinic) Dr. Mazze was also a founder of the affiliated diabetes centre program at Nanjing Medical University where he is appointed visiting professor.

Dr. Sam Dagogo-Jack, USA

Dr. Sam Dagogo-Jack, is Professor in the Division of Endocrinology, Diabetes & Metabolism and Director, General Clinical Research Center at the University of Tennessee, USA. A former President of the American Diabetes Association, he is considered one of the world's leading thought leaders in diabetes. His research has centered around the mechanistic basis of diabetes and Prediabetes. His work has been published widely, in journals such as the Journal of Clinical Endocrinology and Metabolism and Hormone Research. He developed the first radioimmunoassay for epidermal growth factor (EGF) in human saliva, and also- his work with Dr. Philip E. Cryer, led to the discovery of the syndrome of hypoglycemia-associated autonomic failure, paving way to approaches to the management of the same. In addition to cutting edge research work, Dr Sam Dagogo-Jack's commitment to community work, and diabetes awareness programs has been widely acclaimed.

Dr. Suresh Chari, USA

Dr. Chari is currently Professor of Medicine at Mayo Clinic College of Medicine, Rochester, MN.He has been the Director of Pancreas Clinic at Mayo Clinic Rochester and past President of the American Pancreatic Association. He has been a Councilor of the International Association of Pancreatology (IAP) and is the President-Elect of the IAP. He has over 250 publications in the field of pancreatology. His research spans the breadth of pancreatic diseases including tropical chronic pancreatitis and pancreatic cancer. He has had NIH funding since 2003 for study of new-onset Diabetes as an early marker of pancreatic cancer. He is currently conducting a clinical trial of screening for pancreatic cancer in subjects with new-onset Diabetes. He is also interested in the effects of type 1 and type 2 Diabetes on the exocrine pancreas, a condition that he has termed "Diabetic exocrine pancreatopathy".

Dr. Vinaya Simha, USA

Dr. Vinaya Simha, MBBS, MD is a Consultant in the Division of Endocrinology, and Assistant Professor, Department of Internal Medicine at Mayo Clinic, Rochester, MN. He is board certified in Internal Medicine, Endocrinology and Clinical Lipidology. His research interests include lipodystrophy and the role of body fat distribution on glucose and lipid homeostasis, and has many publications in the field of lipodystrophy and leptin-replacement therapy. He has a keen interest in clinical lipidology and is an investigator in some of the early trials of PCSK9 inhibitors.

Dr. William Rust, USA

Dr. William Rust is the Head, Seraxis, and former Director of Cell Biology at the American Type Culture Collection, USA.
Dr. William Rust is among the eminent stem cell researchers in the world. Founder of Seraxis, his work has focused on clinical aspects of stem cell therapy in diabetes. He is a leader in embryonic stem cell therapeutics, and in induced pluripotent stem cell- based treatments. Dr Rust has worked in US and Singapore to develop cell therapies for diabetes and cardiovascular disease. He holds patents, has published in reputed journal, and has been awarded the President's Graduate Fellowship. He is currently working towards clinical studies on a practical cell-based therapy for insulin dependent diabetes.